Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML)

Fourteen patients with acute myelogenous leukaemia, who had either failed to enter remission or had relapsed following conventional chemotherapy, received human lymphoblastoid interferon (Hu IFN-alpha N) at a dose of 100 X 10(6) units/m2 daily by continuous IV infusion for 7 days. Complete remission was not achieved in any of 10 patients evaluable for response, although a transient decrease in the degree of bone marrow infiltration was observed in two patients.